This site is intended for UK healthcare professionals only

Diabetes Professional Care
21-22 October 2025, Olympia London

The UK's leading event for the entire team involved in the prevention, treatment and management of diabetes and its related conditions.

Are you a UK healthcare professional?

We are unfortunately unable to allow patients to attend Diabetes Professional Care

If you would like more information on general practice or primary care, please refer to the NHS website.

Visit the NHS website

Legal Notice

DIABETES PROFESSIONAL CARE IS SUPPORTED BY THE PHARMACEUTICAL AND MED TECH INDUSTRIES VIA GRANTS, SPONSORSHIP, AND EXHIBITION PACKAGES. SESSIONS DELIVERED WITH INPUT FROM OUR SUPPORTERS WILL ALWAYS BE MARKED ON THE PROGRAMME.
A FULL LIST OF CONFIRMED SUPPORTERS FOR DIABETES PROFESSIONAL CARE CAN BE FOUND HERE.
 

News

Subpage Hero

     

07 Jul 2020

Top pharmacist urges more GLP-1s to be given to people

Top pharmacist urges more GLP-1s to be given to people
Victoria Ruszala, who is based in Bristol, thinks more healthcare professionals should be prescribing them because of the huge benefits they have.

She will discuss the subject in more depth along with other key opinion leaders as part of the DPC Summer Form, which was created to disseminate the findings from this year’s ADA's Virtual 80th Scientific Sessions.

Dr David Strain, Dr Patrick Holmes, Dr Marc Evans and Nurse Consultant Debbie Hicks will join Victoria in the online session entitled GLP-1 ADA Round up on Wednesday, July 8 from 7pm.

REGISTER HERE

Victoria said: “GLP-1s can help people who struggle to control their blood glucose levels with positive benefits such as weight loss.

“Usually my role as a pharmacist is to offer an opinion on things like where these drugs would fit in with current treatment pathways.

“GLP-1s are under used at the moment because when NICE originally reviewed them they put a strict set of criteria against them and made them third line therapy. We now have much more high-quality evidence for their benefits and we need to balance this with the potential cost and current confusion as to how we can use them. The tide is turning, but it’s still a fight.”

AstraZeneca provided an arms-length grant for the meetings.

View all News
Loading

Partners

Education Partner

Education Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Event Partner

Media Partner